Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan
Shots:
- Astellas has dosed the first patient with fezolinetant in the 12wk. P-III (STARLIGHT 2) trial to investigate the fezolinetant’s (low dose & high dose, QD) superiority & safety, vs PBO, in Japanese women (n=390) with vasomotor symptoms (VMS) associated with menopause
- The dosing of P-III (STARLIGHT) trials was found based on the results, highlighted at the Annual Meeting of the Japan Society for Menopause and Women’s Health in Dec 2023, from the completed global P-IIb (STARLIGHT) study in 147 participants
- Besides the STARLIGHT 2 study, the company is also evaluating the fezolinetant’s (QD) safety & tolerability, vs PBO, in the 52wk. P-III (STARLIGHT 3) for treating Japanese women (n=260) with the same indication
Ref: Astellas | Image: Astellas
Related News:- Astellas’ Veozah (fezolinetant) Receives the US FDA’s Approval for the Treatment of Vasomotor Symptoms Due to Menopause
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
